The news. The narrative. The timeline.
Bureau: Tokyo
A 108-person Lancet trial of once-weekly semaglutide in patients with alcohol use disorder and obesity cut heavy drinking days by 13.7 points more than placebo and the eligibility line is the story.
The man who told the industry its lax habits would write the failures has died at ninety-three of fall complications, after seventy years of receipts.
Eleven cases, one ship, no new cluster — the operational fact kept whole against panic discourse.